Skip to main content
. Author manuscript; available in PMC: 2023 Feb 21.
Published in final edited form as: Am J Obstet Gynecol MFM. 2022 Aug 24;5(2 Suppl):100731. doi: 10.1016/j.ajogmf.2022.100731

TABLE 2.

Combination drug therapeutic efficacy for prevention of postpartum hemorrhage

Drug combination Study RR of PPH vs placebo or no treatment (95% CI) RR of PPH vs oxytocin alone (95% CI) RR of need for additional uterotonics vs oxytocin alone (95% CI)
Oxytocin–carbetocin Fahmy et al,8 2015 Not quantitatively evaluated
Oxytocin–ergometrine Gallos et al,9 2018
Jaffer et al,10 2022		 0.41 (0.33–0.51)
Not evaluated		 0.70 (0.59–0.84)
Not evaluated		 Not evaluated
0.87 (0.11–6.39)
Oxytocin–misoprostol Gallos et al,9 2018
Jaffer et al,10 2022
Parry Smith et al,11 2020		 0.41 (0.31–0.53)
Not evaluated
Not evaluated		 0.70 (0.58–0.86)
Not evaluated
0.84 (0.66–1.06)		 Not evaluated
0.57 (0.09–3.55)
0.99 (0.94–1.05)
Oxytocin–carboprost No studies to date evaluating this drug–drug combination vs placebo or other therapies
Oxytocin–tranexamic acid No studies to date evaluating this drug–drug combination vs placebo or other therapies

CI, confidence interval; PPH, postpartum hemorrhage; RR, relative risk.